Boule Diagnostics AB Statistics

Total Valuation

Boule Diagnostics AB has a market cap or net worth of SEK 344.84 million. The enterprise value is 505.94 million.

Market Cap	344.84M
Enterprise Value	505.94M

Important Dates

The next estimated earnings date is Tuesday, February 11, 2025.

Earnings Date	Feb 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Boule Diagnostics AB has 38.83 million shares outstanding. The number of shares has increased by 6.31% in one year.

Current Share Class	n/a
Shares Outstanding	38.83M
Shares Change (YoY)	+6.31%
Shares Change (QoQ)	-2.88%
Owned by Insiders (%)	13.73%
Owned by Institutions (%)	57.69%
Float	28.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.62
PB Ratio	1.35
P/TBV Ratio	2.04
P/FCF Ratio	6.46
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.38
EV / Sales	0.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	9.47

Financial Position

The company has a current ratio of 1.04, with a Debt / Equity ratio of 0.70.

Current Ratio	1.04
Quick Ratio	0.70
Debt / Equity	0.70
Debt / EBITDA	n/a
Debt / FCF	3.34
Interest Coverage	-19.14

Financial Efficiency

Return on equity (ROE) is -57.47% and return on invested capital (ROIC) is -24.90%.

Return on Equity (ROE)	-57.47%
Return on Assets (ROA)	-20.80%
Return on Capital (ROIC)	-24.90%
Revenue Per Employee	2.82M
Profits Per Employee	-1.06M
Employee Count	228
Asset Turnover	0.85
Inventory Turnover	4.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.20% in the last 52 weeks. The beta is 0.49, so Boule Diagnostics AB's price volatility has been lower than the market average.

Beta (5Y)	0.49
52-Week Price Change	-11.20%
50-Day Moving Average	7.66
200-Day Moving Average	9.05
Relative Strength Index (RSI)	60.02
Average Volume (20 Days)	74,563

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Boule Diagnostics AB had revenue of SEK 563.33 million and -212.52 million in losses. Loss per share was -5.43.

Revenue	563.33M
Gross Profit	254.31M
Operating Income	-220.20M
Pretax Income	-260.50M
Net Income	-212.52M
EBITDA	-202.26M
EBIT	-220.20M
Loss Per Share	-5.43

Full Income Statement

Balance Sheet

The company has 17.20 million in cash and 178.30 million in debt, giving a net cash position of -161.10 million or -4.15 per share.

Cash & Cash Equivalents	17.20M
Total Debt	178.30M
Net Cash	-161.10M
Net Cash Per Share	-4.15
Equity (Book Value)	254.90M
Book Value Per Share	6.56
Working Capital	8.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 60.58 million and capital expenditures -7.17 million, giving a free cash flow of 53.41 million.

Operating Cash Flow	60.58M
Capital Expenditures	-7.17M
Free Cash Flow	53.41M
FCF Per Share	1.38

Full Cash Flow Statement

Margins

Gross margin is 45.14%, with operating and profit margins of -39.09% and -37.73%.

Gross Margin	45.14%
Operating Margin	-39.09%
Pretax Margin	-46.24%
Profit Margin	-37.73%
EBITDA Margin	-35.90%
EBIT Margin	-39.09%
FCF Margin	9.48%

Dividends & Yields

Boule Diagnostics AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.31%
Shareholder Yield	-6.31%
Earnings Yield	-61.11%
FCF Yield	15.49%

Dividend Details

Stock Splits

The last stock split was on June 1, 2018. It was a forward split with a ratio of 4.

Last Split Date	Jun 1, 2018
Split Type	Forward
Split Ratio	4

Scores

Boule Diagnostics AB has an Altman Z-Score of 0.21. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.21
Piotroski F-Score	n/a